AURIGENE

PHARMACEUTICAL SERVICES



Structural Biology

Uniquely positioned to drive Integrated
Drug Discovery (IDD) program for small and large molecules

Gene to Structural Programs | Complex Targets |
Design to Enhance Crystallizability

Structural Biology

AURIGENE
PHARMACEUTICAL SERVICES

Gene to co-crystal structure service

- Screen in high throughput fashion for co-crystals
  - o Micro and macro seeding for co-crystals
  - o Soaking with small molecules
- Synchrotron data collection for high resolution information
- Molecular replacement structure determination

Gene to novel structure service

- Crystallize novel targets, domain antibody-antigen complexes and protein-protein complexes
- 10,000 unique conditions to screen for initial hits and high throughput optimization
- Molecular replacement or experimental phasing and structure determination from data collected at a synchrotron

Quality attributes to be targeted

- 2.6 Å or better resolution
- >85% completeness
- I/Sig I >1.5 (in highest resolution bin)
- 20 or better R_{work}
- 25 or better and R_{free}
- Bond angle RMSD 0.02
- Bond length RMSD 1.5
- >80% Average correlation co-efficient
- Discernable electron density of ligand (if present)